These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 38647237)

  • 1. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD.
    Ma C; Gu Z; Yang Y
    J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognosis and personalized treatment prediction in lung adenocarcinoma: An
    Ma C; Li F; He Z; Zhao S; Yang Y; Gu Z
    Front Pharmacol; 2023; 14():1113808. PubMed ID: 36874011
    [No Abstract]   [Full Text] [Related]  

  • 3. Crosstalk between copper homeostasis and cuproptosis reveals a lncRNA signature to prognosis prediction, immunotherapy personalization, and agent selection for patients with lung adenocarcinoma.
    Ma C; Gu Z; Ding W; Li F; Yang Y
    Aging (Albany NY); 2023 Nov; 15(22):13504-13541. PubMed ID: 38011277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deciphering disulfidptosis: Uncovering a lncRNA-based signature for prognostic assessment, personalized immunotherapy, and therapeutic agent selection in lung adenocarcinoma patients.
    Ma C; Zhao H; Sun Y; Ding W; Wang H; Li Y; Gu Z
    Cell Signal; 2024 May; 117():111105. PubMed ID: 38369264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma.
    Zhang Y; Jia Q; Li F; Luo X; Wang Z; Wang X; Wang Y; Zhang Y; Li M; Bian L
    Sci Rep; 2024 Mar; 14(1):7543. PubMed ID: 38555384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value and immune landscapes of m1A/m5C/m6A-associated lncRNA signature in osteosarcoma.
    Wu ZY; Shi ZY
    Eur Rev Med Pharmacol Sci; 2022 Aug; 26(16):5868-5883. PubMed ID: 36066162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
    Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
    Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
    Tian L; Wang Y; Tian J; Song W; Li L; Che G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
    Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
    BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
    Cao X; Ji Y; Li J; Liu Z; Chen C
    Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
    Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
    Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
    Wu P; Zheng Y; Wang Y; Wang Y; Liang N
    J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
    Zou X; Hu Z; Huang C; Chang J
    Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a methylomics-associated nomogram for predicting overall survival of stage I-II lung adenocarcinoma.
    Wang H; Wei C; Pan P; Yuan F; Cheng J
    Sci Rep; 2021 May; 11(1):9938. PubMed ID: 33976305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a prognostic model for lung adenocarcinoma based on m6A/m5C/m1A genes.
    Ding H; Teng Y; Gao P; Zhang Q; Wang M; Yu Y; Fan Y; Zhu L
    Hum Mol Genet; 2024 Mar; 33(7):563-582. PubMed ID: 38142284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.